Pulse Biosciences' Chief Operating Officer Liane Teplitsky purchased $99,971 worth of common stock in two open-market transactions executed on August 31 and September 1.
On August 31, Teplitsky acquired 1,024 shares at a weighted average price of $48.80 per share, with individual prices ranging from $48.76 to $48.80. The following day, she purchased an additional 1,001 shares at $49.95 each. Post-transaction, her beneficial ownership totals 4,095 shares, valued at approximately $216,000 at current market prices.
The transactions occurred as Pulse Biosciences' stock surged 284% year-to-date, reaching $52.68, near its 52-week high of $54.39. The company's Q2 2026 financial results, however, underperformed expectations. Adjusted loss per share widened to $0.36, exceeding the Wall Street consensus of a $0.28 loss, while revenue of $400,000 fell short of the $600,000 forecast. Pulse Biosciences cited ongoing progress in its pivotal atrial fibrillation trial, thyroid and surgical programs, and advancements in its nanosecond pulsed field ablation system.
Analysts have adjusted their outlook following the stock's rally. Canaccord raised its price target from $32 to $43 while maintaining a Buy rating. Needham initiated coverage with a Buy rating and a $58 target, citing the development of the company's next-generation pulse field ablation platform technology. InvestingPro analysis, however, indicates the stock appears overvalued relative to its fair value.
